BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26690706)

  • 1. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.
    Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; de Jong RN; Beurskens FJ; Schuurman J; Parren PW; Taylor RP
    Mol Immunol; 2016 Feb; 70():13-23. PubMed ID: 26690706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
    Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
    J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.
    Cook EM; Lindorfer MA; van der Horst H; Oostindie S; Beurskens FJ; Schuurman J; Zent CS; Burack R; Parren PW; Taylor RP
    J Immunol; 2016 Sep; 197(5):1762-75. PubMed ID: 27474078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
    Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
    Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
    J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
    Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
    J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
    Lefebvre ML; Krause SW; Salcedo M; Nardin A
    J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.
    Beum PV; Lindorfer MA; Peek EM; Stukenberg PT; de Weers M; Beurskens FJ; Parren PW; van de Winkel JG; Taylor RP
    Eur J Immunol; 2011 Aug; 41(8):2436-46. PubMed ID: 21674476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
    Kennedy AD; Solga MD; Schuman TA; Chi AW; Lindorfer MA; Sutherland WM; Foley PL; Taylor RP
    Blood; 2003 Feb; 101(3):1071-9. PubMed ID: 12393727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.
    Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP
    Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
    Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
    Front Immunol; 2020; 11():609941. PubMed ID: 33505398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.
    Beers SA; Chan CH; James S; French RR; Attfield KE; Brennan CM; Ahuja A; Shlomchik MJ; Cragg MS; Glennie MJ
    Blood; 2008 Nov; 112(10):4170-7. PubMed ID: 18583569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies.
    Okroj M; Österborg A; Blom AM
    Cancer Treat Rev; 2013 Oct; 39(6):632-9. PubMed ID: 23219151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of alemtuzumab on neoplastic B cells.
    Golay J; Manganini M; Rambaldi A; Introna M
    Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.
    Beum PV; Lindorfer MA; Beurskens F; Stukenberg PT; Lokhorst HM; Pawluczkowycz AW; Parren PW; van de Winkel JG; Taylor RP
    J Immunol; 2008 Jul; 181(1):822-32. PubMed ID: 18566448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.
    Church AK; VanDerMeid KR; Baig NA; Baran AM; Witzig TE; Nowakowski GS; Zent CS
    Clin Exp Immunol; 2016 Jan; 183(1):90-101. PubMed ID: 26307241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.
    Nishida M; Uematsu N; Kobayashi H; Matsunaga Y; Ishida S; Takata M; Niwa O; Padlan EA; Newman R
    Int J Oncol; 2011 Feb; 38(2):335-44. PubMed ID: 21152859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
    Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
    Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.